/ 0 " 3
Issue 21,23 3 Spring 2014
4
" Prestigious awards to Conway Researchers 1 ! The Sir Henry Wellcome postdoctoral % scheme aims to fellowship provide the
promising 5 6
most newly qualified researchers with a postdoctoral unique (67 -! ! opportunity to develop independent research ! careers. For8 ! the first time, the 5 this Wellcome Trust has awarded $
fellowship to an ' Irish early career !
7 researcher, Dr Colm Ryan.
1
9 4
: (9 4 :- Dr Ryan will work with Prof Walter Kolch, % ! 5 Systems Biology Ireland and Prof Alan 6
$
Ashworth, Institute of Cancer Research,
London to investigate how genetic changes impact on a targeted approach to cancer ! " treatment.
# $
in " % A major challenge cancer therapeutics is & " other to kill tumour cells without harming $
have
cells in the body. Cancer cells genetic that " % changes distinguish them from healthy
cells, and consequently may leave them ' (" ) "
vulnerable treatments. to targeted *+ , - A promising approach to $ developing .
" such targeted " treatments to identify
" " % is. genes
" whose function is only essential for survival cancer-associ in the presence of a specific % ated mutation. Such a phenomenon, where the function of gene A becomes essential
/" # only in the presence of a mutation in gene " -+ B, is called synthetic lethality. However, + % " little is understood about how additional +% "
genetic differences between individuals might impact on their use.
" lethality " impact on synthetic treatments,
" treat and investigating whether certain be more
genetic ments might robust to differences than others. " %
The 11th Luke’s Young . St " " Investigator " award was won by Irish Cancer Society research fellow, Dr Maria Prencipe at the Royal "
College Physicians of Ireland on January
% . of 29th 2014. *01., % ' " This prestigious award supported the
by Royal Academy of Medicine in Ireland and " St " Luke’s Radiation Oncology
Network, " work to Dublin went to Dr Prencipe for her " 01.% for castration find a new molecular target resistant prostate cancer (CRPC).
- 23 " " Dr Maria Prencipe colleagues and working with Fellow, Prof William Watson Conway " " recently identified the transcription factor $% 4 " named serum response factor as an (SRF) " important target in CRPC using and " genetic computational analyses. " "
%
$ "
head-on, clinicians and scientists need to mechanisms
% understand the underlying of resistance.
' (" " “Our study shows evidence of cross-talk "
" between receptor (AR) androgen " and SRF in advanced prostate cancer. At the core of / 5 " ' ' this cross-talk is a negative loop feedback between SRF and AR that were able to we
" demonstrate in vitro, clinical samples and " " in is % supported by a computational model�,
said Dr Prencipe. Prof Walter Kolch, Director & 6. both Maria
on said, â&#x20AC;&#x153;I congratulate Colm and (" " their achievements. It is fitting " " ! " recognition for their dedication to fundamental cancer research and " improving outcomes for patients with 5 " %7 advanced diseaseâ&#x20AC;?. " " 8 + % + & 9 : 0 : : . . 1 1 + + : . : : ' (" ;% + ' % 23 3 / 22< ==*>,?@A >@
When prostate cancer is detected early in
0 "
patients, surgery and radiation
" " " " treatments are effective therapies. Patients $ " with locally advanced and metastatic prostate cancer are treated with androgen
ablation (hormone depletion or chemical " " castration) therapy. "
Despite an initial response, the majority of men progress to develop castration-resistant prostate cancer which, despite the emergence of new treatments, is challenging to treat. To meet this challenge
Dr Maria Prencipe
) /
Dr Ryanâ&#x20AC;&#x2122;s fellowship will focus on understanding how such genetic changes
Directorâ&#x20AC;&#x2122;s Message
1
8 8
;
Welcome!
" " facilities In the last quarter, the dedicated for Systems Biology Ireland adjacent $ to Conway Institute became UCD " (" operational; new director of UCD " the
$ Charles Institute of Dermatology, Prof
% . Martin Steinhoff joined UCD from " B ' University of California San Francisco; and ' =3 the Institute hosted the first UCD Ireland ;- 23 ;- " A East cancer open house. " %
4 " C " < The UCD Ireland East cancer open house / " provided a unique opportunity for cancer " " " " survivors, patient advocacy groups and
clinicians from across the Ireland East " " network to sit at the laboratory bench and %
talk with researchers about the projects they are working on in the battle against 4 cancer. The dedication and passion of our
was -+ evident early career researchers clearly $
and, in turn, they were inspired by the " who individuals might ultimately benefit " " from this research.
Dr Colm Ryan " / 0 23 3%
0 developments " many These create " " and integrative interfaces for collaboration undoubtedly " strengthen impact and will the Instituteâ&#x20AC;&#x2122;s priority of strategic
" + building a strong translational medicine programme. " "
Professor Walter Kolch "
% Director
B 4 : -+ + 0 "
<2:4 <7' ' ' 1 '0 / D;+-D E '0 /; 0+ D ; ; +&